Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Medtronic
Dow
AstraZeneca
Express Scripts

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,066,992

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,066,992
Title:Polymers for implantable devices exhibiting shape-memory effects
Abstract: The present invention is directed to polymeric compositions comprising a biodegradable copolymer that possesses shape-memory properties and implantable devices (e.g., drug-delivery stents) formed of materials (e.g., a coating) containing such compositions. The polymeric compositions can also contain at least one non-fouling moiety, at least additional biocompatible polymer, at least one biobeneficial material, at least one bioactive agent, or a combination thereof. The polymeric compositions are formulated to possess good mechanical, physical and biological properties. Moreover, implantable devices formed of materials comprising such compositions can be delivered to the treatment site in a conveniently compressed size and then can expand to dimensions appropriate for their medical functions.
Inventor(s): Stankus; John J. (Campbell, CA), Trollsas; O. Mikael (San Jose, CA), Ngo; Michael H. (San Jose, CA)
Assignee: Abbott Cardiovascular Systems Inc. (Santa Clara, CA)
Application Number:13/903,773
Patent Claims:1. A composition comprising a biodegradable copolymer comprising at least two segments A and B, wherein: the A segment has a T.sub.g or T.sub.m in the range from about 50.degree. C. to about 300.degree. C. and is made from at least one diisocyanate and at least one diol, diamine or dithiol chain extender; the B segment has a T.sub.g or T.sub.m in the range from about 30.degree. C. to about 100.degree. C. and is derived from a polymer containing at least one hydroxyl, amino or thiol end group; the T.sub.g or T.sub.m of the A segment is at least about 20.degree. C. greater than the T.sub.g or T.sub.m of the B segment; the A and B segments each independently have a polymer number-average molecular weight (M.sub.n) from about 0.4, kDa to about 500, kDa; and wherein: the composition displays at least one shape-memory effect, and a permanent shape of the composition is obtained when the temperature of the composition is equal to or greater than the T.sub.g or T.sub.m of the B segment; wherein at least one dihydroxyaryl group is conjugated to the end(s) of the copolymer.

2. The composition of claim 1, wherein the A segment has a T.sub.g or T.sub.m in the range from about 70.degree. C. to about 260.degree. C. and the B segment has a T.sub.g or T.sub.m in the range from about 35.degree. C. to about 70.degree. C.

3. The composition of claim 2, wherein the T.sub.g or T.sub.m of the B segment is in the range from about 35.degree. C. to about 40.degree. C.

4. The composition of claim 1, wherein the T.sub.g or T.sub.m of the A segment is at least about 40.degree. C. greater than the T.sub.g or T.sub.m of the B segment.

5. The composition of claim 1, wherein the B segment is derived from a polymer comprising from one to four different types of monomer, wherein each type of monomer has from about 5, to about 5,000, monomer units.

6. The composition of claim 1, wherein the A segment is made from one to four different polycondensation reactions involving a diisocyanate and a diol, diamine or dithiol chain extender, wherein each polycondensation reaction: occurs from about 5 to about 5,000 times, and involves a diisocyanate and a diol, diamine or dithiol chain extender that may be the same as or different than any other diisocyanate(s) and any other diol, diamine or dithiol chain extender(s) involved in any other polycondensation reaction(s).

7. The composition of claim 1, wherein the biodegradable copolymer further comprises a third segment A', and wherein the A' segment: is made from at least one diisocyanate and at least one diol, diamine or dithiol chain extender; has an M.sub.n from about 0.4 kDa to about 500 kDa; may be attached to the B segment or the A segment; and may be the same as or different than the A segment.

8. The composition of claim 7, wherein the A' segment is made from one to four different polycondensation reactions involving a diisocyanate and a diol, diamine or dithiol chain extender, wherein each polycondensation reaction: occurs from about 5 to about 5,000 times, and involves a diisocyanate and a diol, diamine or dithiol chain extender that may be the same as or different than any other diisocyanate(s) and any other diol, diamine or dithiol chain extender(s) involved in any other polycondensation reaction(s).

9. The composition of claim 7, wherein the A' segment is attached to the B segment.

10. The composition of claim 7, wherein the A' segment is attached to the A segment.

11. The composition of claim 7, wherein the A and A' segments are the same.

12. The composition of claim 7, wherein the A and A' segments are different.

13. The composition of claim 12, wherein the A' segment has a T.sub.g or T.sub.m in the range from about -70.degree. C. to about 100.degree. C.

14. The composition of claim 13, wherein the A' segment has a T.sub.g or T.sub.m in the range from about -20.degree. C. to about 35.degree. C.

15. The composition of claim 1, wherein the B segment is derived from a polyester containing at least one hydroxyl end group selected from the group consisting of polycaprolactone (PCL) diol, poly(.beta.-hydroxy-alkanoate-diol), poly([R]-3-hydroxybutyrate-diol), poly(L-lactide) (PLLA) diol, poly(D,L-lactide) diol, polyglycolic acid, polyglycolide (PGA) diol, poly(trimethylene carbonate) (PTMC) diol, polydioxanone diol, polyvalerolactone diol, polypropiolactone diol, polyacetal, and hydroxyl-terminated random or block copolymers thereof.

16. The composition of claim 15, wherein the polyester containing at least one hydroxyl end group is selected from the group consisting of poly(trimethylene carbonate) (PTMC) diol, polydioxanone diol, polyvalerolactone diol, polypropiolactone diol, polyacetal, and hydroxyl-terminated random or block copolymers thereof.

17. The composition of claim 16, wherein the hydroxyl-terminated random or block copolymer is selected from the group consisting of poly(glycolide-co-trimethylene carbonate), poly(caprolactone-co-trimethylene carbonate), poly(glycolide-co-trimethylene carbonate-co-caprolactone), and any variations in the arrangement of the monomers thereof.

18. The composition of claim 1, wherein the B segment further comprises at least one non-fouling moiety.

19. The composition of claim 18, wherein the at least one non-fouling moiety is selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, poly(ethylene oxide-co-propylene oxide) surfactants, poly(2-hydroxyethyl methacrylate) (PHEMA), poly(vinyl alcohol) (PVA), polyalkene oxides, poly(n-propylmethacrylamide), poly(N-vinyl-2-pyrrolidone) (PVP), sulfonated polystyrene, dextran, sulfonated dextran, dextrin, hyaluronic acid, sodium hyaluronate, and derivatives thereof.

20. The composition of claim 1, wherein the A segment is made from at least one aliphatic diisocyanate.

21. The composition of claim 20, wherein the at least one aliphatic diisocyanate is selected from the group consisting of 1,2-diisocyanatoethane, 1,3-diisocyanatopropane, 1,4-diisocyanatobutane, 1,5-diisocyanatopentane, 1,6-diisocyanatohexane, 1,4-diisocyanatocubane, and lysine diisocyanate.

22. The composition of claim 1, wherein the A segment is made from at least one diol, diamine or dithiol chain extender selected from the group consisting of ethylene glycol, 1,3-propanediol, 1,2-propanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, 1,12-dodecanediol, 1,2-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, the corresponding diamine and dithiol analogs thereof, lysine ethyl ester, arginine ethyl ester, p-alanine-based diamine, and random or block copolymers made from at least one diisocyanate and at least one diol, diamine or dithiol chain extender.

23. The composition of claim 1, wherein the B segment is immiscible with the A segment.

24. The composition of claim 1, wherein the copolymer is thermoplastic.

25. The composition of claim 1, wherein the copolymer is thermoset.

26. The composition of claim 1, further comprising at least one additional biocompatible polymer.

27. The composition of claim 26, wherein the at least one biocompatible polymer is selected from the group consisting of poly(ethylene glycol) (PEG); polypropylene; poly(propylene glycol) (PPG); poly(N-vinyl pyrrolidone) (PVP); poly(N-vinyl pyrrolidone-co-vinyl acetate) (Copovidone); poly(ester amides) (PEA); acrylic acid (AA); polyacrylates; acrylamides; fluorinated polymers or copolymers; poly(hydroxyvalerate); poly(L-lactic acid)/polylactide (PLLA); poly(.epsilon.-caprolactone); poly(lactide-co-glycolide) (PLGA); poly(hydroxybutyrate); poly(hydroxyvalerate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoesters; polyanhydrides; poly(glycolic acid)/polyglycolide (PGA); poly(D,L-lactic acid) (PLA); poly(glycolic acid-co-trimethylene carbonate); polyphosphoesters; polyurethanes; polyureas; polyurethane(ureas); poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonates); co-poly(ether-esters); polyalkylene oxalates; polyphosphazenes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-.alpha.-olefin copolymers; vinyl halide polymers and copolymers; polyvinyl ethers; polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics; polyvinyl esters; copolymers of vinyl monomers with each other; olefins; poly(vinyl alcohol) (PVA); acrylonitrile butadiene (ABS) resins; ethylene-vinyl acetate copolymers; polyamides; alkyl resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; rayon; rayon-triacetate; and combinations and co-polymers thereof.

28. The composition of claim 1, further comprising at least one biobeneficial material.

29. The composition of claim 28, wherein the at least one biobeneficial material is selected from the group consisting of fibrin; fibrinogen; cellulose and cellulose derivatives; starch; pectin; chitosan; elastin, gelatin; alginate and conjugates thereof; collagen and conjugates thereof; hyaluronan and derivatives thereof; hyaluronic acid; sodium hyaluronate; and self-assembled peptides (SAP).

30. The composition of claim 1, further comprising at least one biologically active agent selected from the group consisting of antiproliferative, antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances.

31. The composition of claim 30, wherein the at least one biologically active agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(2-ethoxy)ethyl-rapamycin (biolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (zotarolimus), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, bioactive RGD, CD-34, antibody, abciximab (REOPRO), progenitor cell-capturing antibodies, prohealing drugs, prodrugs thereof, co-drugs thereof, and a combination thereof.

32. A coating comprising the composition of claim 1.

33. A coating comprising the composition of claim 30.

34. A coating comprising the composition of claim 31.

35. An implantable device formed of a material comprising the composition of claim 1.

36. The implantable device of claim 35, wherein the material is a coating disposed over the device.

37. The implantable device of claim 35, which is selected from the group consisting of stents, grafts, stent-grafts, catheters, leads and electrodes, clips, shunts, closure devices and valves.

38. An implantable device formed of a material comprising the composition of claim 30.

39. The implantable device of claim 38, wherein the material is a coating disposed over the device.

40. The implantable device of claim 38, which is selected from the group consisting of stents, grafts, stent-grafts, catheters, leads and electrodes, clips, shunts, closure devices and valves.

41. An implantable device formed of a material comprising the composition of claim 31.

42. A method of preparing the composition of claim 1, comprising: performing polycondensation of a diisocyanate and a diol, diamine or dithiol chain extender with a B segment polymer containing at least one hydroxyl, amino or thiol end group, and optionally performing additional polycondensation reaction(s) with additional diisocyanate(s) and additional diol, diamine or dithiol chain extender(s); conjugating at least one dihydroxyaryl group to the polymer ends of the copolymer.

43. A method of fabricating an implantable device, comprising forming the device of material comprising the composition of claim 1.

44. A method of fabricating an implantable device, comprising forming the device of material comprising the composition of claim 30.

45. A method of treating or preventing a condition or disorder in a patient, comprising implanting in the patient an implantable device comprising a coating formed of a material comprising the composition of claim 1, wherein the condition or disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection, vascular perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, arteriovenous anastamoses, bile duct obstruction, ureter obstruction and tumor obstruction.

46. The method of claim 45, wherein the condition or disorder is selected from atherosclerosis, thrombosis, restenosis, and vulnerable plaque.

47. The method of claim 45, further comprising providing a thermal stimulus to the device if the T.sub.g or T.sub.m of the B segment is greater than body temperature.

48. The method of claim 45, wherein the composition further comprises at least one biologically active agent selected from the group consisting of antiproliferative, antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances.

49. The method of claim 48, wherein the at least one biologically active agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(2-ethoxy)ethyl-rapamycin (biolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (zotarolimus), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, bioactive RGD, CD-34, antibody, abciximab (REOPRO), progenitor cell-capturing antibodies, prohealing drugs, prodrugs thereof, co-drugs thereof, and a combination thereof.

50. The method of claim 45, wherein the implantable device is selected from the group consisting of stents, grafts, stent-grafts, catheters, leads and electrodes, clips, shunts, closure devices and valves.

51. The composition of claim 1, wherein the dihydroxyaryl group contains a 3, 4-dihydroxyphenyl moiety or a 1, 2-dihydroxyphenyl moiety.

52. The composition of claim 51, wherein the 3, 4-dihydroxyphenyl moiety is formed from 3,4-dihydroxyhydrocinnamic acid or dopamine.

53. A method of preparing a composition of claim 12, wherein the A' segment is different than the A segment; wherein when the A' segment is attached to the B segment to form A-B-A' trisegment copolymer, the method comprising the following steps: performing polycondensation of a diisocyanate and a diol, diamine or dithiol chain extender with a B segment polymer containing a free hydroxyl, amino or thiol end group and a protected hydroxyl, amino or thiol end group; optionally performing additional polycondensation reaction(s) with additional diisocyanate(s) and additional diol, diamine or dithiol chain extender(s); protecting the functional group formed at the polymer end of the A segment; deprotecting the protected hydroxyl, amino or thiol end group of the B segment; performing polycondensation of a diisocyanate and a diol, diamine or dithiol chain extender with the deprotected hydroxyl, amino or thiol end group of the B segment; optionally performing additional polycondensation reaction(s) with additional diisocyanate(s) and additional diol, diamine or dithiol chain extender(s); and optionally deprotecting the protected functional group at the polymer end of the A segment; or wherein when the A' segment is attached to the A segment to form A'-A-B trisegment copolymer, the method comprising the following steps: performing polycondensation of a diisocyanate and a diol, diamine or dithiol chain extender with a B segment polymer containing a free hydroxyl, amino or thiol end group and a protected hydroxyl, amino or thiol end group; optionally performing additional polycondensation reaction(s) with additional diisocyanate(s) and additional diol, diamine or dithiol chain extender(s); performing polycondensation of a diisocyanate and a diol, diamine or dithiol chain extender with the deprotected hydroxyl, amino or thiol end group of the A segment; optionally performing additional polycondensation reaction(s) with additional diisocyanate(s) and additional diol, diamine or dithiol chain extender(s); and optionally deprotecting the protected functional group at the polymer end of the B segment.

Details for Patent 9,066,992

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Request a Trial Abbott Cardiovascular Systems Inc. (Santa Clara, CA) 2027-08-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Mallinckrodt
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.